

WEDI NOS

The logo for WEDI NOS is displayed in a bold, black, sans-serif font. The word "WEDI" is on the top line and "NOS" is on the bottom line. A red ECG (heart rate) line is superimposed over the text, starting from the left, passing through the 'E' in "WEDI", and continuing across the top of "NOS". A white silhouette of a person stands within the vertical bar of the 'I' in "WEDI". A grey shadow is cast to the right of the person silhouette and the "NOS" text.

Collecting • Testing • Informing



April 2023

- 485 samples analysed (12 CJS, 51 NTE, 422 community submissions)
 - 81 substances identified either in isolation or combination
 - Samples received from across UK
 - 36 services
 - Including: Health, Substance Misuse Services, Mental Health, Housing and Homelessness, Night Time Economy venues, Welsh Emergency Departments and Welsh Prisons
 - Alongside samples submitted anonymously by individuals

Sex / age profile of sample providers



- Sex (where listed n=411 of 422 community samples)
 - Male: 80% (n= 329)
 - Female:20% (n=82)
- Age
 - Range: 8 to 70yrs (Median: 33yrs)
 - Male age range: 16 to 62yrs (Median: 33yrs)
 - Female age range: 8 to 70yrs (Median: 28yrs)

Community Submissions

(comparing top 10 purchase intent vs top 10 post analysis)


No.	Community purchase intent	Community post analysis
1	Diazepam	Diazepam
2	MDMA	Cocaine
3	Alprazolam	Bromazolam
4	Cocaine	MDMA
5	Ketamine	Ketamine
6	Tetrahydrocannabinol	Alprazolam
7	Zopiclone	Caffeine
8	Amphetamine	Zopiclone
9	Etizolam	Amphetamine
10	Pregabalin	Etizolam

Benzodiazepines

- 13 Benzodiazepines identified
 - Diazepam (89 purchase intent / 53 identifications)
 - Bromazolam (0 purchase intent / 51 identifications)
 - Alprazolam (44 purchase intent / 21 identifications)
 - Etizolam (8 purchase intent / 12 identifications)
 - Flualprazolam (1 purchase intent / 7 identifications)
 - Clonazepam
 - Clonazolam
 - Flubromazepam
 - Deschloroetizolam
 - Lorazepam
 - Bromazepam
 - Clobromazolam

**Purchase intent and
identifications <5**


Contents of samples submitted as Diazepam: Apr 2023 (n=90)



Diazepam sample providers:

Age range: 19 to 62yrs
Median: 35yrs

Contents of samples submitted as Alprazolam: Apr 2023 (n=44)



Alprazolam sample providers:

Age range: 21 to 70yrs
Median: 30yrs

Nitazene identified in samples submitted as Oxycodone



Two samples submitted as oxycodone, were found to contain the nitazene, metonitazene. Information on Nitazenes is available in February's Philtre

W032792

Date Received: 28 Apr 2023

Postcode: SN3 -

Purchase Intent: Oxycodone

Package Label: Not Stated

Sample Colour: Yellow

Sample Form: Tablet

Consumption Method: Oral

Self-Reported Effects: Relaxed, Irregular Heartbeat, Nausea, Vomiting, Loss of consciousness

Sample Upon Analysis (Major): Metonitazene

Sample Upon Analysis (Minor):



[Click to Enlarge](#)

W032808

Date Received: 28 Apr 2023

Postcode: BS2 -

Purchase Intent: Oxycontin/Fentanyl

Package Label: Oxycontin

Sample Colour: Yellow

Sample Form: Tablet

Consumption Method: Not Stated

Self-Reported Effects: Not Stated

Sample Upon Analysis (Major): Metonitazene

Sample Upon Analysis (Minor):



[Click to Enlarge](#)

Xylazine found in sample submitted as Codeine



- Xylazine is a partial alpha-2 adrenergic agonist, non-opioid, sedative analgesic medication used as a veterinary tranquilliser for non-human mammals.
- Xylazine has been identified as a substance of misuse, primarily as an adulterant in the heroin and cocaine market in Puerto Rico and the United States of America.
- The most common features include drowsiness, coma, bradycardia and hypotension. Other features may include hypertension, hypothermia, respiratory depression, apnoea, agitation, hallucinations, headache, dry mouth, hyperglycaemia, cardiac arrhythmias (including AV block), pulmonary oedema and convulsions.

W032638

Date Received: 24 Apr 2023

Postcode: UB10 -

Purchase Intent: Codeine phosphate

Package Label: Codeine phosphate (accord)

Sample Colour: White

Sample Form: Tablet

Consumption Method: Not Stated

Self-Reported Effects: Not Stated

Sample Upon Analysis (Major): xylazine

Sample Upon Analysis (Minor):



[Click to Enlarge](#)

Naloxone, responding to a xylazine overdose



- In the event of a suspected xylazine overdose, experts recommend giving the opioid overdose reversal medication naloxone because xylazine has been evidenced to be frequently combined with opioids.
- However, because xylazine is not an opioid, naloxone does not address the impact of xylazine on breathing. As a result, additional care may be necessary in the treatment of a xylazine overdose. This may include maintaining a patent airway, administering supplemental oxygen, performing rescue breathing and treating hypotension as needed.
- TOXBASE and the UK National Poisons Information Service highlight xylazine as a Highly Toxic Substance, and all patients should be referred to an Emergency Department after exposure to any amount by any route